Truist lowered the firm’s price target on Inspire Medical (INSP) to $235 from $250 and keeps a Buy rating on the shares. The company’s Q4 ...

Baird lowered the firm’s price target on Inspire Medical (INSP) to $248 from $252 and keeps an Outperform rating on the shares. The firm said ...

The improved performance came in the period premiums from medical insurance rose 22.8 percent to Sh46.3 billion.

RBC Capital Markets upheld a positive outlook on Inspire Medical Systems (NYSE:INSP) shares, reiterating an Outperform rating with a steady price target of $260.00. The stock currently trades at $180.

If enacted in 2022, the Fair Pricing Act could have saved patients up to $213.4 million in out-of-pocket costs, research says.

Since abrdn's acquisition in 2023, HQL has delivered a total return of 25.5%, though its price appreciation has been modest.

Truist Securities adjusted its price target for Inspire Medical Systems (NYSE:INSP) stock, lowering it from $250.00 to $235.00 while maintaining a Buy rating. The adjustment follows the company's ...

A coalition of 22 attorneys general sued the federal government, claiming that the $4 billion in cuts would “grind to a halt” ...

United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s ‘life-changing’ inhaler, suit ...

Lisa Quarrell has been campaigning tirelessly for six years to have her youngest son’s lifesaving medical cannabis prescribed ...

MIDF Research is optimistic on the healthcare sector despite anticipated changes and updates to existing policies and ...

Looking for the best bargain shares to buy before April's investing deadline? Here are two hot FTSE 250 shares offering great ...